Scott Blumberg

“As Jane highlighted, total revenue for the third quarter of 2026 was $29.3 million, which is an approximately 30% increase from $22.6 million in the third quarter of 2025 and a 4% sequential increase.”

“So Cerebel is a publicly traded medical technology company that makes brainwave monitoring, EEG, much quicker. And we've overlaid that with a number of AI-powered algorithms to help detect serious neurological conditions that affect people in the acute care setting, which is the emergency room in the ICU.”

“First of all, the two things I'd like to point out in the Q2 OPEX that were a little bit out of the normal is stock-based compensation sequentially increasing by about $2.3 million.”

“What Cerebell has developed is a novel point-of-care electroencephalobically, or EEG, platform that targets a variety of serious neurological conditions in the acute care setting, so the ICU and the ED.”

“Sure, Stephanie, as you alluded, there's really two core drivers for our core seizure market. and I'm sure we'll get into the pipeline soon, but one is accounts added, two is usage per account.”